B. Riley Financial Varied
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MacroGenics, Inc. - Common Stock (NQ:MGNX)

1.835 +0.135 (+7.94%)
Streaming Delayed Price Updated: 11:23 AM EST, Jan 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MacroGenics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings For Macrogenics ↗
 
Via Benzinga
MacroGenics Inc. (NASDAQ: MGNX) Leading the Way in Thursday Trading Based on Percentage Gain
Via Investor Brand Network
News headline image
Macrogenics: Q4 Earnings Insights ↗
 
Via Benzinga
News headline image
Nasdaq Moves Lower; US Consumer Sentiment Falls In May ↗
 
Via Benzinga
News headline image
MacroGenics Shares Tumble After Reporting Adverse Events, Multiple Deaths In Cancer Drug Trial ↗
Latest interim data from TAMARACK Phase 2 study by MacroGenics unveils insights into vobramitamab duocarmazine targeting B7-H3 in metastatic prostate cancer. Despite responses, notable safety concerns... 
Via Benzinga
Topics Death
News headline image
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against MacroGenics, Inc. and Encourages Investors to Contact the Firm
From Schall Law
Via GlobeNewswire
News headline image
Dow Jumps Over 100 Points; DNOW Posts Downbeat Earnings ↗
 
Via Benzinga
Topics Stocks
News headline image
Why Is Progyny (PGNY) Stock Down 27% Today? ↗
Progyny stock is down on Friday after the company posted a revenue miss for Q1 and disappointed PGNY investors with its guidance! 
Via InvestorPlace
News headline image
Why Natera Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Why Is Macrogenics (MGNX) Stock Down 69% Today? ↗
Macrogenics stock is down on Friday as MGNX investors react to clinical trial deaths and missed earnings for the first quarter of 2024. 
Via InvestorPlace
Topics Death
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗
The biggest pre-market stock movers are ready to go as we check out all of the hottest news happening on Friday morning! 
Via InvestorPlace
News headline image
Akamai Technologies Issues Weak Outlook, Joins Applied Optoelectronics, JFrog And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
MacroGenics (MGNX) Q1 2024 Earnings Call Transcript ↗
MGNX earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
MGNX Stock Earnings: Macrogenics Misses EPS, Misses Revenue for Q1 2024 ↗
MGNX stock results show that Macrogenics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
MacroGenics Announces Date of First Quarter 2024 Financial Results Conference Call
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
Masters In Trading - Saturday, April 27 ↗
In this recap of the most recent trading session, I review my portfolio and share one of the trades taken this week. 
Via Talk Markets
News headline image
Look Out For These 6 Stocks As Analysts Predicts Major Gains, One Up To 82% ↗
Investment analysts have revised their price targets upwards for six major stocks this week, with one company expected to see an 82% surge. The revised targets include four U.S.-listed companies, with... 
Via Benzinga
News headline image
MacroGenics Analyst Impressed By Improved Safety Profile From Prostate Cancer Candidate ↗
Update on MacroGenics Inc's Phase 2 TAMARACK study of vobramitamab duocarmazine (vobra duo) for metastatic castration-resistant prostate cancer (mCRPC). Safety and preliminary efficacy data anticipated... 
Via Benzinga
News headline image
Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Shares of STAAR Surgical Company (NASDAQ: STAA) rose sharply during Thursday’s session after the company issued strong preliminary first-quarter net sales guidance. STAAR Surgical shares jumped 13.3%... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Simulations Plus Posts Upbeat, Joins Levi Strauss, BlackBerry And Other Big Stocks Moving Higher In Thursday's Pre-Market Session ↗
U.S. stock futures were higher this morning, with the Dow futures gaining by around 90 points on Thursday. 
Via Benzinga
Topics Stocks
News headline image
MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures
From MacroGenics, Inc.
Via GlobeNewswire
News headline image
MacroGenics (MGNX) Q4 2023 Earnings Call Transcript ↗
MGNX earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
News headline image
MGNX Stock Earnings: Macrogenics Misses EPS for Q4 2023 ↗
MGNX stock results show that Macrogenics missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Earnings Scheduled For March 7, 2024 ↗
Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
B. Riley Financial's diverse suite of services goes beyond traditional financial service offerings. By leveraging cross-platform expertise and assets, B. Riley Financial companies are uniquely positioned to provide full service, collaborative solutions to our clients at every stage of the business life cycle and in all market conditions.

B. Riley refers to B. Riley Financial, Inc. and/or one or more of its subsidiaries or affiliates. Click here for further details.